Correction to: Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer

Shunsuke Kondo,Masaomi Tajimi, Tomohiko Funai,Koichi Inoue,Hiroya Asou, Vinay Kumar Ranka,Volker Wacheck,Toshihiko Doi

INVESTIGATIONAL NEW DRUGS（2020）

引用 4|浏览9

暂无评分

摘要

The article Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer, written by Shunsuke Kondo, Masaomi Tajimi, Tomohiko Funai, Koichi Inoue, Hiroya Asou, Vinay Kumar Ranka, Volker Wacheck, Toshihiko Doi, was originally published electronically on the publisher’s internet portal on 23 June 2020 without open access.

查看译文

关键词

LY3023414, Advanced malignancies, Dose-escalation study, Japanese patients, Safety

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要